BioSpace News Archive

Bio-Techne Corporation, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, announced it has reached an agreement to acquire Lunaphore, Inc.

Kanvas Biosciences, the leader in microbiome mapping technology, announced today a $12M Pre-Series A funding round.

BioMarin Pharmaceutical Inc. today announced it will present new data from the ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy clinical trial program.

The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute, for her seminal discovery that a mutation in a specific human gene causes systemic lupus erythematosus, uncovering an important target for the development of novel treatment.

Inhibikase Therapeutics, Inc. today announced that it has selected the bioequivalent dose of IkT-001Pro, the Company’s prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib (marketed as Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) and provided an update on its ‘501' bioequivalence study.

Eyenuk has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras.

Schrödinger, Inc. today reported that on June 16, 2023, the company granted (i) non-statutory stock options to purchase 14,325 shares of the company’s common stock to 11 newly hired employees and (ii) restricted stock units (RSUs) with respect to 11,138 shares of the company’s common stock to 11 newly hired employees.

Aptorum Group Limited announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA.

Lunaphore Technologies SA , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced it has reached an agreement to be acquired by Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors.